Marché mondial des systèmes de guidage des lésions mammaires – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse du marché et de la taille des systèmes de guidage des lésions mammaires

Le marché mondial des systèmes de guidage des lésions mammaires devrait connaître une croissance significative au cours de la période de prévision. Un tiers des cancers du sein diagnostiqués chaque année dans le monde sont subtils, et ce niveau augmente à mesure que les programmes de dépistage deviennent plus répandus et que des modalités plus avancées telles que l'IRM détectent davantage de lésions cliniquement potentielles. Il s'agit d'une méthode non chirurgicale sûre et précise pour diagnostiquer des anomalies suspectes sur les images mammaires et elle est essentielle pour une prise de décision appropriée, y compris la planification du traitement.

Data Bridge Market Research analyse le taux de croissance du marché mondial des systèmes de guidage des lésions mammaires au cours de la période de prévision 2022-2029. Le TCAC attendu du marché mondial des systèmes de guidage des lésions mammaires a tendance à être d'environ 5,50 % au cours de la période de prévision mentionnée. Le marché était évalué à 250 millions USD en 2021 et devrait atteindre 383,67 millions USD d'ici 2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de recherche sur le marché de Data Bridge comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché des systèmes de guidage des lésions mammaires

Market Definition

Cardiac disease is often overlooked on cardiac CT. However, the soft tissue function of the multi-detector CT is sufficient for reliable diagnosis. Breast lesions or injuries are abnormal changes in breast tissue caused by the disease or injury, and breast lesion locating procedures are used to detect, diagnose, and treat diseases or injuries associated with breast tissue. Appropriate guidance systems will lead to the growth of the market.

Global Breast Lesion Guidance Systems Market Dynamics

Drivers

• Increased Prevalence of Breast Cancer

Breast cancer is among the most common diseases affecting women in developed and developing countries. According to the American Cancer Society, breast cancer is the second leading cause of cancer related deaths in women across the globe. Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.

•  Increased Elderly Population

With age, the risk of developing breast cancer increases. With aging, pluripotent progenitor cells (a type of adult stem cell at the root of many breast cancers) increase, lining breast lactating lumen cells, and reducing the number of myoepithelial cells that function as tumor suppressors. According to the American Cancer Society, about one-eighth of invasive breast cancers occur in women under the age of 45. In contrast, women over the age of 55 develop about two-thirds of invasive breast cancers.

Opportunities

• Funding For Research and clinical activities

Increasing funding for R&D activities for the treatment of oncological diseases by various regulators and some state governments is also expected to boost the growth of the global laboratory development testing market.

• Emerging Economy

Emerging markets such as India, China, Brazil, South Korea, Turkey, Russia and South Africa offer significant growth opportunities for key players operating in the breast lesion guidance market. The large population base of India and China in particular provide a sustainable market for medical and surgical devices as a whole. Emerging market governments are also investing heavily in the development and modernization of healthcare infrastructure. For instance, according to OECD data, China's health care costs in 2020 was $ 810.8 per person. Similarly, Brazil spent about 9.5% of its GDP on health care in 2020, according to health care and financial data. The Brazilian Ministry of Health and several non-governmental agencies have also made efforts to improve early detection in the country and promote breast cancer screening and education.

Restraints/Challenges

• Lack of skilled oncologists

Breast cancer surgery and lesion locating procedures are performed by experienced professionals to achieve better results. These surgeries are considered to be at higher risk than other surgeries due to various challenges such as tumor localization, risk of removal of healthy tissue, lymphedema, and seroma. Similarly, the use of radioactive substances may increase the risk of patients developing radiation-induced cancer. Radiation exposure has several short-term and long-term side effects, usually occurring within 6 months or 1 year of exposure. The most common side effects after radiation exposure include mild pain and discomfort around the breast, skin damage, swelling and inflammation of the breast and surrounding tissues, hair loss on the flanks and breasts, and fatigue. Radiation exposure can also damage nerves in the arms, hands, and chest. To mitigate these risks, the localization procedure requires trained operators and radiologists who must go through a certification process to perform localization of breast lesions.

• Uncertainty in regulatory approval procedures

Regulatory authorities such as the U.S. FDA need comprehensive clinical data to demonstrate the clinical safety and efficacy of approved products. Due to the stringent regulatory requirements for product approval, market players in methods of locating breast lesions (especially radioisotope locating) are nuclear regulated by the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. You need to get approval for. This approval process is so long and capital intensive that it is difficult for small manufacturers and companies with limited budgets to compete in this market.

This breast lesion guidance systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the breast lesion guidance systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Breast Lesion Guidance Systems Market

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period.

The COVID19 pandemic has serious implications for the diagnostic and therapeutic procedures for all non-COVID19 diseases worldwide. This has also impacted the market for breast lesion locating methods, as the adverse effects of COVID19 on people with pandemic-related blockades and comorbidities have significantly reduced attendance at hospitals, clinics and diagnostic centres. In response to COVID 19, many countries have suspended breast screening programs. For instance, in Canada, the Netherlands, Germany, Italy, the United Kingdom and Australia, national screening programs have been completely suspended for one to six months. Therefore, while the market under study was affected by the COVID 19 pandemic, the market under study regains its potential with continued vaccination and a reduction in the number of COVID 19 cases during the forecast period.

Global Breast Lesion Guidance Systems Market Scope

The Global breast lesion guidance systems market is segmented on the basis of type, usage and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Wire
• Radioisotope
• ROLL
• RSL
• Magnetic
• Electromagnetic Localization

Usage

• Breast Biopsy
• Lumpectomy

End-User

• Selection Criteria
• Replacement Trend

Global Breast Lesion Guidance Systems Market Regional Analysis/Insights

The breast lesion guidance systems market is analysed and market size insights and trends are provided by country, type, usage and end-user as referenced above.

The major countries covered in the breast lesion guidance systems market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the breast lesion guidance system market in recent years and is expected to show similar trends over the forecast period due to the high number of breast cancer cases, primarily coupled with strong medical infrastructure and the presence of the breast.

Asia-Pacific region is expected to grow at a significant growth rate during the forecast period of 2022 t0 2029 due to the improving healthcare infrastructure, increasing government funds on breast cancer research, and rapidly rising awareness about the importance of the early detection of breast cancer in several APAC countries.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Breast Lesion Guidance Systems Market Share Analysis

The breast lesion guidance systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to breast lesion guidance systems market.

Key players operating in the breast lesion guidance systems market include:

• BD (US)
• C.R. Bard, Inc. (US)
• Devicor Medical Products Inc. (US)
• Hologic Inc. (US)
• Merit Medical Systems (US)
• Leica Biosystems Nussloch GmbH (US)
• Argon Medical Devices (US)
• Laurane Medical LLC (France)
• Endomagnetics Ltd. (UK)
• Intramedical Imaging, LLC (US)
• Isoaid (US)
• Surgiceye GmbH (Germany)
• Ranfac Corp. (US)
• Mermaid Medical Group (Denmark)
• Izi Medical Products, LLC (US)
• Matek Medikal (Turkey)
• Tsunami Medical Srl (Italy)
• BPB Medica (Italy)
• Sirius Medical Systems B.V. (Netherlands)
• Molli Surgical Inc. (Canada)
• Sterylab S.R.L. (Italy)
• CP Medical (Georgia)
• MDL SRL (Italy)
• Biomedical Srl (Italy)
• Elucent Medical (US)
• Vigeo srl (Italie)
• Dispositifs médicaux Medax (Italie)

SKU-68833